TY - JOUR T1 - SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis JF - Gut JO - Gut DO - 10.1136/gutjnl-2022-328451 SP - gutjnl-2022-328451 AU - Anand V Kulkarni AU - Chandan S Metage AU - Baqar Ali Gora AU - Sowmya Tirumalle AU - Kalyan Rakam AU - Anveshi Satyavadi AU - Mithun Sharma AU - Sameer Shaik AU - Deepika Gujjarlapudi AU - Padaki Nagaraja Rao AU - D Nageshwar Reddy Y1 - 2022/09/16 UR - http://gut.bmj.com/content/early/2022/09/15/gutjnl-2022-328451.abstract N2 - Dufour et al highlighted that the effect of COVID-19 in patients with cirrhosis is derived from the prevaccination era and suggested that the impact of Omicron infection in patients with cirrhosis needs to be elucidated.1 We agree with the author that previous studies have reported significant morbidity and mortality in patients with cirrhosis infected with SARS CoV-2 in the prevaccination era.2–7 To our knowledge, no studies have assessed the impact of Omicron infection in patients with cirrhosis. Therefore, we aimed to compare the outcomes of Omicron infection among patients with cirrhosis and without cirrhosis.We retrospectively included non-cirrhotic (NC) patients and patients with cirrhosis from 1 January 2022 to 1 March 2022 diagnosed with Omicron infection. Omicron BA.1 variant was identified based on the S-gene dropout on the reverse transcriptase PCR test. In the absence of S-gene drop-out, Omicron BA.2 variant was confirmed by assessing the presence of Q954H mutation. The primary outcome was to compare the mortality, and the secondary was to compare the other essential outcomes,8 including long COVID-19 effects among both groups (online supplemental figure 1). The severity of COVID-19 was graded based on Indian … ER -